Clinical trials: Tirzepatide, completed
Type 2 Diabetes Mellitus
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
- Trial name
- SURPASS-CVOT (NCT04255433)
- Testing
- Tirzepatide, Dulaglutide
- Where
- 635 sites in United States, Argentina and 29 more
- Volunteers
- 13,299 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Obesity
Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy
To assess whether holding incretin-based therapy before endoscopy reduces the likelihood of clinically relevant Residual Gastric Volume (RGV).
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Gastroparesis
- Trial name
- NCT06533527
- Testing
- GLP-1 medication
- Where
- 2 sites in United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
The main purpose of this phase 3b study is to evaluate the efficacy and safety of tirzepatide compared with semaglutide in adult participants who have obesity or overweight with weight related comorbidities without Type 2…
- Trial name
- SURMOUNT-5 (NCT05822830)
- Testing
- Tirzepatide, Semaglutide
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 751 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
The main purpose of this study is to investigate the efficacy and safety of Tirzepatide monotherapy in Chinese participants with Type 2 Diabetes.
- Trial name
- NCT05963022
- Testing
- Tirzepatide
- Where
- 28 sites in China
- Volunteers
- 206 people
- Sponsor
- Eli Lilly and Company
Type2 Diabetes, Diabetes Mellitus
A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both
The purpose of this study is to learn more about the safety and efficacy of tirzepatide compared to placebo in children or teenagers with type 2 diabetes taking metformin, or basal insulin, or both.
- Conditions
- Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D
- Trial name
- SURPASS-PEDS (NCT05260021)
- Testing
- Tirzepatide Dose 1, Tirzepatide Dose 2
- Where
- 51 sites in United States, Australia and 7 more
- Volunteers
- 99 people
- Sponsor
- Eli Lilly and Company
Obesity
A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity
The main purpose of this study is to evaluate the safety and tolerability of tirzepatide (LY3298176) in pediatric participants with obesity.
- Trial name
- NCT05696847
- Testing
- Tirzepatide
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
The main purpose of this study is to assess the efficacy and safety of Tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity.
- Trial name
- NCT04847557
- Testing
- Tirzepatide
- Where
- 146 sites in United States, Argentina and 8 more
- Volunteers
- 731 people
- Sponsor
- Eli Lilly and Company
Diabetes Type 2, Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
The main purpose of this study is to compare the effect of the addition of tirzepatide or placebo to titrated basal insulin on glycemic control in Chinese participants with type 2 diabetes.
- Conditions
- Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease
- Trial name
- SURPASS-CN-INS (NCT05691712)
- Testing
- Tirzepatide
- Where
- 25 sites in China
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH)
The main purpose of this study is to investigate the efficacy and safety of switching from weekly dulaglutide to weekly tirzepatide compared to increasing the dulaglutide dose in adults with type 2 diabetes.
- Trial name
- SURPASS-SWITCH (NCT05564039)
- Testing
- Tirzepatide, Dulaglutide
- Where
- 38 sites in United States, Belgium and 3 more
- Volunteers
- 282 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase.
- Trial name
- SURMOUNT-1 (NCT04184622)
- Testing
- Tirzepatide
- Where
- 118 sites in United States, Argentina and 8 more
- Volunteers
- 2,539 people
- Sponsor
- Eli Lilly and Company
Obstructive Sleep Apnea, Obesity
Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea
The purpose of this study is to evaluate the effect and safety of tirzepatide in participants with moderate to severe obstructive sleep apnea and obesity who are both unwilling or unable to use Positive Airway Pressure (PAP)…
- Trial name
- SURMOUNT-OSA (NCT05412004)
- Testing
- Tirzepatide
- Where
- 58 sites in United States, Australia and 8 more
- Volunteers
- 469 people
- Sponsor
- Eli Lilly and Company
Healthy
A Study of Tirzepatide (LY3298176) in Healthy Lactating Females
The main purpose of this study was to look if the study drug, tirzepatide, gets into the breastmilk and, if yes, how long it takes the body to get rid of it from the breastmilk.
- Trial name
- NCT05978713
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Nonalcoholic Steatohepatitis
A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)
The purpose of this study is to see if the study drug, tirzepatide administered once weekly, is safe and effective as a treatment for Nonalcoholic Steatohepatitis (NASH).
- Trial name
- SYNERGY-NASH (NCT04166773)
- Testing
- Tirzepatide
- Where
- 112 sites in United States, Belgium and 8 more
- Volunteers
- 190 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes, Diabetes Mellitus, Type 2
A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)
The main purpose of this study is to investigate the effects of switching from glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy to tirzepatide glucose-dependent insulinotropic polypeptide (GIP) GLP-1 RA agonist in…
- Trial name
- NCT05706506
- Testing
- Tirzepatide
- Where
- 32 sites in United States
- Volunteers
- 152 people
- Sponsor
- Eli Lilly and Company
Healthy
A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices
The main purpose of this study is to look at the amount of the study drug, tirzepatide, that gets into the blood stream and how long it takes the body to get rid of it when given using two different devices.
- Trial name
- NCT05810597
- Testing
- Tirzepatide, Single Dose Pen, Multi-use Prefilled Pen
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity
A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease
The main purpose of this study is to learn more about tirzepatide in participants with obesity disease. The study will also measure how Tirzepatide affects body weight with a low-calorie diet and increased physical activity.
- Trial name
- SURMOUNT-J (NCT04844918)
- Testing
- Tirzepatide
- Where
- 18 sites in Japan
- Volunteers
- 267 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of Tirzepatide in Overweight and Very Overweight Participants
The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight.
- Trial name
- NCT04311411
- Testing
- Tirzepatide, Liraglutide
- Where
- 3 sites in United States
- Volunteers
- 114 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
This was a study of tirzepatide in participants with obesity or overweight. The main purpose was to learn more about how tirzepatide maintained body weight loss.
- Trial name
- SURMOUNT-4 (NCT04660643)
- Testing
- Tirzepatide
- Where
- 70 sites in United States, Argentina and 3 more
- Volunteers
- 783 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Hypoglycemia
A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to learn more about how tirzepatide affects the body's response to low blood sugar (hypoglycemia). The study is open to participants with type 2 diabetes.
- Trial name
- NCT04050553
- Testing
- Tirzepatide
- Where
- Austria
- Volunteers
- 42 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program.
- Trial name
- SURMOUNT-3 (NCT04657016)
- Testing
- Tirzepatide
- Where
- 65 sites in United States, Argentina and 2 more
- Volunteers
- 579 people
- Sponsor
- Eli Lilly and Company